More Images
Low doses of lithium aspartate did not successfully treat neurologic symptoms of long COVID, a randomized, double-blind, placebo-controlled trial showed.

In a study of 52 people with long COVID, lithium aspartate at 10 to 15 mg/day yielded no significant improvement in fatigue and cognitive dysfunction scores at 3 weeks compared with placebo, reported Thomas Guttuso Jr., MD, of the University at Buffalo in New York, and co-authors in JAMA Network Open.

The primary endpoint was the change in the sum of Fatigue Severity Scale-7 (FSS-7) and Brain Fog Severity Scale (BFSS) scores. Scores for each scale can range from 7 to 49, with higher scores indicating more severe symptoms.

"Although this finding is preliminary, I believe it provides some degree of hope for long COVID patients," Guttuso said. "Another randomized controlled trial needs to be performed using higher dosages to determine if lithium may be effective for long COVID fatigue and brain fog," he told MedPage Today. Head over to MedPage Today to read more about it.